http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160126734-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0624908c7150e45bdd907be4f162057e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0696 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-074 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86 |
| filingDate | 2015-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fa80353ab32f296b9caec76789cad1f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79153ec9662de9f03de2c25e8a9879ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8822d93f0a3b96798e57919e0b2db5f |
| publicationDate | 2016-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20160126734-A |
| titleOfInvention | A method for producing autoimmune disease patient-specific induced pluripotent stem cell and a use thereof |
| abstract | According to the present invention, provided is a manufacturing method of an induced pluripotent stem cell which is specific to a patient suffering from an autoimmune disease such as ankylosing spondylitis, Sjogrens syndrome, or systemic lupus erythematosus. The induced pluripotent stem cell is manufactured using an uninserted vector and nicotinamide, and a reprogramming factor is not inserted into a genome. The manufacturing method of an induced pluripotent stem cell can solve a problem caused as a reprogramming factor is inserted into a genome. The manufacturing method of an induced pluripotent stem cell has greatly excellent reprogramming efficiency in comparison with an existing manufacturing method, and can provide an autoimmune disease patient-specific induced pluripotent stem cell. Furthermore, according to the present invention, the induced pluripotent stem cell is developed into a target cell, and can be practically used for a personalized disease model, a drug screening method, and a cell replacement therapy. The manufacturing method of an induced pluripotent stem cell comprises the following steps: (a) transmitting a reprogramming factor to a cell isolated from an autoimmune disease patient by using uninserted vector; and (b) cultivating the cell obtained in the step (a) in a culture medium including nicotinamide. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018133139-A1 |
| priorityDate | 2015-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 296.